Literature DB >> 24225744

Splenic lymphoid subsets with less well-recognized phenotypes mimic aberrant antigen expression.

Nidhi Aggarwal1, Jason Fischer, Steven H Swerdlow, Fiona E Craig.   

Abstract

OBJECTIVES: Flow cytometry can assist in the diagnosis of lymphoma by identifying aberrant antigen expression. Recognition of aberrancy requires knowledge of the phenotype of normal lymphoid cells.
METHODS: Lymphoid subsets were characterized in 20 spleens removed for traumatic rupture, using 8-color flow cytometry.
RESULTS: Normal variation in splenic lymphoid subsets was highlighted and several well-recognized subsets were identified: CD5+ B cells (20/20 specimens), CD7- T cells (20/20), and CD3 brightγδT cells (16/20). In addition, less well-recognized lymphoid subsets that resemble those described in lymphoma were identified in all specimens: CD5- T cells (4.5 ± 5.1% of T cells), CD2- natural killer (NK) cells (38 ± 7% of NK cells), and CD7dim+ NK cells. Similar populations were identified in 20 control peripheral blood specimens, where they represented a smaller proportion of total lymphoid cells.
CONCLUSIONS: Familiarity with the phenotype of normal lymphoid subsets can help prevent misinterpreting flow cytometric data. Furthermore, in the context of neoplastic cells, the phenotype may suggest expanded normal subsets rather than aberrant antigen expression.

Entities:  

Keywords:  Aberrant; Flow cytometry; Phenotype; Spleen

Mesh:

Substances:

Year:  2013        PMID: 24225744     DOI: 10.1309/AJCPPIBH3I1VRWXQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  PhenoGraph and viSNE facilitate the identification of abnormal T-cell populations in routine clinical flow cytometric data.

Authors:  Joseph A DiGiuseppe; Jolene L Cardinali; William N Rezuke; Dana Pe'er
Journal:  Cytometry B Clin Cytom       Date:  2017-09-26       Impact factor: 3.058

2.  Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.

Authors:  Kathryn E Cole; Quan P Ly; Michael A Hollingsworth; Jesse L Cox; Kurt W Fisher; James C Padussis; Jason M Foster; Luciano M Vargas; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2022-02-21       Impact factor: 4.932

3.  Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.

Authors:  Kathryn E Cole; Quan P Ly; Michael A Hollingsworth; Jesse L Cox; James C Padussis; Jason M Foster; Luciano M Vargas; James E Talmadge
Journal:  Cell Immunol       Date:  2021-03-01       Impact factor: 4.868

4.  Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.

Authors:  Tomoki Yoneyama; Mi-Sook Kim; Konstantin Piatkov; Haiqing Wang; Andy Z X Zhu
Journal:  PLoS Comput Biol       Date:  2022-07-15       Impact factor: 4.779

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.